Literature DB >> 28675914

Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome.

Chantal Di Segni1, Andrea Silvestrini2, Romana Fato3, Christian Bergamini4, Francesco Guidi5, Sebastiano Raimondo1, Elisabetta Meucci2, Daniela Romualdi5, Rosanna Apa5, Antonio Lanzone5, Antonio Mancini1.   

Abstract

Introduction Insulin resistance (IR) is associated with polycystic ovary syndrome (PCOS). Oxidative stress (OS) is, in turn, related to IR. Studies in PCOS evidenced an increase in OS markers, but they are mainly performed in obese patients, while the complex picture of normal weight PCOS is still poorly investigated. Matherials and Methods To investigate OS in PCOS and relationship with hormonal and metabolic picture, we performed a case-control study in 2 PCOS groups: normal weight (N-PCOS, n=21, age 18-25 ys, mean±SEM BMI 20.7±0.2 kg/m2) and obese (OB-PCOS, n=15, 20-30 ys, BMI 32.8±1.1), compared with control groups matched for BMI: normal (N-C, n=10, 20-30 ys, BMI 21.6±0.9) and obese (OB-C, n=20, 21-31ys, BMI 36.8±1.0). Malondialdehyde (MDA) in blood plasma and peripheral mononuclear cells, obtained by density-gradient centrifugation, was assayed spectrophotometrically by TBARS assay. CoenzymeQ10 (CoQ10) in plasma and cells was assayed by HPLC. Plasma Total Antioxidant Capacity (TAC) was also measured by spectrophotometric method. Results PCOS patients exhibited higher Testosterone levels than controls, but OB-PCOS had highest HOMA (Homeostasis Model Assessment) index, suggesting marked insulin resistance. Despite plasma MDA levels were not significantly different (N-PCOS 3380±346.94 vs. N-C 7 120±541.66; OB-PCOS 5 517.5±853.9 vs. OB. 3 939.66±311.2 pmol/ml), intracellular MDA levels were significantly higher in N-PCOS than controls (mean 3 259±821.5 vs. 458±43.2 pmol/106/cells) and higher than OB-PCOS, although not significantly (1363.1±412.8 pmol/106/cells). Intracellular CoenzymeQ10 was higher in N-PCOS than in N-C, but the highest levels were found in OB-C. Conclusions Our data, while confirming the presence of OS in obese PCOS patients in agreement with literature, suggest that OS could be present also in normal weight PCOS, but it can be revealed in tissue rather than in plasma. The relationship with metabolic status remains to be established, but could be a physiopathological basis for antioxidant treatment in such patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28675914     DOI: 10.1055/s-0043-111241

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  4 in total

Review 1.  What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment.

Authors:  Daniela Romualdi; Valeria Versace; Antonio Lanzone
Journal:  Ther Adv Reprod Health       Date:  2020-02-27

Review 2.  Life Modifications and PCOS: Old Story But New Tales.

Authors:  Yuanyuan Gu; Guannan Zhou; Fangyue Zhou; Qiongwei Wu; Chengbin Ma; Yi Zhang; Jingxin Ding; Keqin Hua
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-13       Impact factor: 6.055

3.  Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality.

Authors:  Yue Liu; Zhiheng Yu; Shigang Zhao; Lei Cheng; Yuanyuan Man; Xueying Gao; Han Zhao
Journal:  J Assist Reprod Genet       Date:  2020-11-20       Impact factor: 3.412

Review 4.  Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing.

Authors:  Hosna Mohammad Sadeghi; Ida Adeli; Daniela Calina; Anca Oana Docea; Taraneh Mousavi; Marzieh Daniali; Shekoufeh Nikfar; Aristidis Tsatsakis; Mohammad Abdollahi
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.